In this randomized double-blind study, 4 groups of healthy subjects (50 per arm) participated to evaluate the effect of laquinimod, an oral treatment in development for multiple sclerosis and Huntington disease, on the QTc interval. Subjects received a dose of either 0.6 or 1.2 mg/day laquinimod for 14 days, placebo for 14 days, or 13 days of placebo followed by a dose of 400 mg moxifloxacin on day 14. Continuous 12-lead electrocardiograms were recorded on day -1 (baseline) and days 14 to 17, and quadruplicate electrocardiograms were extracted at predefined time points. The primary measure was time-matched change from baseline in individual QTc (QTcI), and an analysis of variance was conducted on the placebo-corrected change from baseline data (ddQTcI). Pharmacokinetic-pharmacodynamic and safety assessments were included. Results showed that the upper limits of the 2-sided 90%CI for ddQTcI for both laquinimod doses were below 10 millisconds at all time points, whereas lower limits for moxifloxacin were above 5 milliseconds. No notable changes in ECG parameters were observed. Pharmacokinetic/pharmacodynamic analysis showed no positive correlation between laquinimod plasma levels and QTcI. In conclusion, laquinimod was not found to affect cardiac repolarization or to cause prolongation of QTcI at doses of 0.6 and 1.2 mg/day.
Laquinimod (TV-5600, Teva Pharmaceuticals, Netanya, Israel) is a quinoline-3-carboxamide derivative in clinical development as a once-daily oral treatment for multiple sclerosis (MS) and Huntington disease. Laquinimod passively enters the blood-brain barrier, is detectable in central nervous system tissues and modulates immune-mediated inflammatory pathways involved in neurodegenerative diseases. 1 Preclinical data in various experimental models of MS suggest that, in the periphery, laquinimod downregulates monocytic activity and proinflammatory cytokine secretion, 2, 3 whereas in the central nervous system, laquinimod downregulates microglia and astrocytic activation, 4 both of which are believed to be involved in demyelination, axonal and neuronal damage, and decreased levels of brain-derived neurotrophic factor. 5 Treatment of mice with laquinimod is associated with alterations in the frequency of myeloid subpopulations that included a reduction in CD4 + dendritic cells. Laquinimod treatment also promoted the development of antiinflammatory type II monocytes and dendritic cells, [2] [3] [4] which are likely associated with its immunomodulatory activities. These activities include reduced production of proinflammatory cytokines such as IL-17, reduced migration of lymphocytes, 3, 5 augmentation of regulatory T-cell numbers 3, 6 and production of brainderived neurotrophic factor. 5, 7 These immunomodulatory effects of laquinimod in experimental autoimmune encephalomyelitis are mediated via the aryl hydrocarbon receptor, the molecular target of laquinimod in experimental autoimmune encephalomyelitis. 8 Laquinimod is considered to have high oral bioavailability with linear time-and dose-independent and predictable pharmacokinetics (PK) that is characterized by low clearance (0.09 L/h), low volume of distribution (ß10 L), long terminal half-life (ß80 hours), and high protein binding (>98%) over a wide dose range. Absorption under fasting conditions is rapid, and maximal plasma levels are attained generally within 1 hour after administration. 9 As expected from its half-life, laquinimod reaches steady-state concentrations within approximately 14 days of dosing, accumulates in plasma approximately 5-to 6-fold, and fluctuation during the 24-hour dosing interval is low (about 30%). The intersubject variability in laquinimod PK parameters is generally low, with coefficient of variation of about 20% across the different studies. 10 In vitro human microsomal studies suggest that laquinimod metabolism is mediated by CYP3A4. 11 Three phase 3, placebo-controlled studies in relapsing-remitting MS (ALLEGRO, BRAVO, and CONCERTO) have been completed. [12] [13] [14] A phase 2 study for treatment of primary progressive MS (ARPEGIO) and a phase 2 study for treatment of Huntington disease (LEGATO) are currently ongoing. The safety profile of laquinimod from the previous studies in MS patients at doses of 0.3 and 0.6 mg/day included benign or manageable adverse events (AEs) and asymptomatic laboratory findings with a clear temporal pattern.
In a good laboratory practice (GLP)-compliant in vitro human ether-a-go-go-related gene (hERG) test using HEK293 cells stably transfected with hERG cDNA, 15, 16 laquinimod did not have any effect on the hERG tail current at concentrations up to 30 μmol/L (as opposed to the positive control E-4031), providing exposures approximately 28-fold higher than the total maximal drug concentrations (C max ) in human plasma at doses of 0.6 mg/day. With binding of laquinimod to plasma proteins taken into account, safety margins from the hERG test are approximately 1500-fold higher than the unbound C max of laquinimod in plasma. In addition, no effect on the cardiac action potential was observed when laquinimod was tested in a GLP-compliant study using Purkinje fibers isolated from beagle dogs at concentrations from 15 and up to 1500 nmol/L, as opposed to the positive control cisapride, which caused an increase of the action potential duration. Furthermore, a GLP-compliant in vivo cardiovascular safety study conducted in 4 anesthetized dogs (2/gender) found no cardiovascular effects following single intravenous doses of laquinimod from 0.2 up to 20 mg/kg (data on file, Teva Pharmaceuticals Ltd). Although these data suggest that laquinimod is unlikely to prolong the cardiac action potential and QT interval in humans, a clinical study in accordance with the E14 regulatory guidance 17 was conducted to further assess this.
The primary objective of this thorough QT (TQT) study was to estimate the effects of multiple dosing of laquinimod 0.6 mg/day (clinical dose) and 1.2 mg/day (supratherapeutic dose) on QTc prolongation. A positive control (moxifloxacin) was included in the study to demonstrate assay sensitivity because a single dose of 400 mg was consistently demonstrated to cause mean maximal QTc prolongations of 10-15 milliseconds.
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Methods
Study Population
Healthy subjects aged 18 to 45 years old, having a body mass index between 18 and 30 kg/m 2 , and judged to be in good health, as determined through medical history, 12-lead electrocardiograms (ECGs), vital signs, clinical laboratory tests, and physical examinations, were included in the study. Subjects were excluded if they had a resting Bazett-corrected or Fridericia-corrected QT (QTcB or QTcF, respectively) value less than 300 milliseconds and/or greater than 450 milliseconds in males or greater than 470 milliseconds in females. Other exclusion criteria included a QRS segment longer than 120 milliseconds, a history or risk factors for Torsades de Pointes (including a family history of arrhythmias, sudden death, or long-QT syndrome), a supine heart rate outside of 45 to 90 beats/min (bpm) (following at least a 10-minute rest), or a supine blood pressure outside of 90 to 140 mm Hg systolic or 45 to 90 mm Hg diastolic (following at least a 10+-minute rest). Subjects were also excluded if they used any over-the-counter medications or herbal remedies within 14 days before first study drug administration, medications known to be inhibitors or inducers of CYP3A enzyme activity, or any drug known to prolong the QT interval within 30 days before first study drug administration. The only exceptions were use of hormonal contraceptives by female subjects and occasional paracetamol or ibuprofen. This study was conducted during January-May 2008 in accordance with the guidelines set forth by the International Conference on Harmonisation (ICH) Guidelines for Good Clinical Practice (ICH Guideline E6), 19 the US Code of Federal Regulations for Good Clinical Practice (21 CFR Parts 50 and 56), 20 and the Declaration of Helsinki regarding the treatment of human subjects in a study. 21 The protocol was approved the PRACS Institute, Ltd. Independent Review Board (Fargo, North Dakota) and was conducted at the PRACS-Cetero Research site in Fargo, North Dakota. All participants provided written informed consent prior to participation in the study.
Study Design
This was a 4-arm, double-blind, randomized, parallelgroup study. Subjects received either 0.6 or 1.2 mg/day laquinimod for 14 days, placebo for 14 days, or 13 days of placebo followed by a single dose of 400 mg encapsulated moxifloxacin on day 14. A double-dummy method was employed to maintain the double-blind status of the study. Laquinimod tablets (0.6 mg) and matching, placebo tablets were of identical appearance. Moxifloxacin (Avelox, Bayer Healthcare AG, Leverkusen, Germany) and placebo for moxifloxacin capsules (Teva Pharmaceutical Industries Ltd, Netanya, Israel) were overencapsulated in an identical manner to ensure identical appearance.
A comparative dissolution study between encapsulated moxifloxacin tablets and marketed moxifloxacin tablets was performed to demonstrate that the encapsulation of the marketed product does not affect the dissolution of the drug and hence is not expected to have any effect on its bioavailability. Testing was conducted on 12 original tablets and 12 encapsulated tablets, using a paddle apparatus with sinkers, rotating at 75 rpm. The tablets were dissolved in 900 mL gastric fluid, and samples were drawn after 15, 20, 25, and 30 minutes. The quantitation of the percentage of moxifloxacin dissolved was conducted using UV spectroscopy with detection set at 295 nm.
Subjects were screened for eligibility within 28 days of study participation and were randomly assigned to 1 of the 4 groups with approximately equal numbers of male and female subjects in each group. Subjects were admitted to the clinical site 2 days before study drug administration. Treatments were administered once daily on days 1 to 14, and subjects were discharged from the clinical site on day 17, 3 days after the last dose, and had their exit visit on day 28, 14 days after the last dose.
For treatment administration, all subjects received their respective study drugs in the morning after fasting overnight. Subjects were requested to remain in a supine or semisupine position for the first 2 hours postdose.
Pharmacodynamic ECG Measurements
ECGs were collected using high-resolution digital continuous 12-lead ECG devices (Mortara H12+ [100 Hz], Mortara Instruments Inc, Milwaukee, Wisconsin) at 0.5, 1, 1.5, 3, 4, 6, 9, 12, 18, and 24 hours postdose on day -1 (baseline) and day 14, and at 36, 48, and 72 hours after the last dose. Subjects were resting in a comfortable supine position for at least 15 minutes before each ECG sampling time point and remained in a resting position at least 10 minutes after the sampling time point. At each time point the 4 ECGs were extracted from 10-second waveforms 1 minute apart from each other. ECGs were read centrally (eResearch Technology, Inc, Philadelphia, Pennsylvania) by qualified technicians using a semiautomatic, high-resolution, on-screen caliper method with annotations. Central ECG overread was provided by certified cardiologists. ECG analysis was conducted on lead II or, when that was not analyzable, lead V5 or the most appropriate lead. The readers were blinded to subject and study drug details and timing of ECGs, and a single reader read all ECGs for a given subject.
Pharmacokinetic Methods
Blood samples for measuring laquinimod plasma levels were aimed at characterizing the steady-state pharmacokinetics of laquinimod and thus collected from all subjects at baseline, on days 12, 13, and 14 at predose and on day 14 at 0.5, 1, 1.5, 3, 4, 6, 9, 12, 18, 24, 36, 48, and 72 hours postdose. ECGs were performed approximately 10 minutes before the scheduled time point; after that blood samples for pharmacokinetic analysis were collected at the scheduled time points.
Blood samples from the laquinimod treatment arms were analyzed using bioanalytical liquid chromatography-tandem mass spectrometry (LC-MS/MS) method, which involves deproteinization of human plasma using 13 C 6 -laquinimod as an internal standard. The samples were centrifuged at 5000 rpm for 10 minutes at room temperature, and supernatant was transferred to high-precision LC amber glass vials for injection. Chromatographic separation was made using Hypersil BDS, 3 μm, 50 × 2.1 mm column (Agilent 1100 LC pump) and mobile phase elution (gradient steps of of 0.01% trifluoroacetic acid in methanol and 0.01% trifluoroacetic acid in water) following with MS/MS detection. LC-MS/MS analysis was carried out using a SCIEX API2000 mass spectrometer that was connected to the HPLC system via a TIS interface operated at 550°C. The MS/MS detector was run in turbo ion-spray (positive ion) multiple-reaction monitoring mode. The mass spectrometer was programmed to admit the protonated molecules via the first quadrupole filter (Q1) with collision-induced fragmentation at Q2; the product ions were monitored via Q3. The precursor and product ion masses (m/z) were monitored at Q1 and Q3 as follows: laquinimod m/z at Q1 357 amu, at Q3 236 amu, and 13 C 6 -laquinimod at Q1 363 amu and at Q3 236 amu. Back-calculated concentration percentages resulted in mean precision and accuracy of <5% with no calibration and/or quality control samples out of ±15% criteria. The method was validated at Teva Pharmaceutical Works Private Ltd Co, with a low quantitation limit of 2.5 ng/mL. The method is linear, accurate, and precise in the range of 2.5-1000 ng/mL for laquinimod.
Pharmacokinetic analysis was performed using actual sampling time points and standard noncompartmental methods (Phoenix WinNonlin version 5.0.1, Certara, Princeton, New Jersey). All plasma concentrations below the limit of quantitation occurring at predose and up to the first measurable concentration were imputed as 0; otherwise values were treated as missing. The maximum observed plasma concentration (C max ), the time of its occurrence (T max ), and minimum plasma concentration (C min ) were directly obtained from each individual concentration time profile. The area under the plasma concentration-time curve over the dosing interval on day 14 (AUC 24 ) was calculated using the linear trapezoidal method.
Safety Assessments
Safety was evaluated throughout the study by monitoring adverse events, clinical laboratory parameters, bedside 12-lead ECGs, vital signs (blood pressure, pulse rate, respiratory rate, and body temperature), physical examinations, and the use of concomitant medications.
Statistical Methods
The sample size of 50 subjects per group was based on the noninferiority of laquinimod against placebo in the primary analysis, based on a conservative standard deviation of 9-10 milliseconds 22 and a true difference between time-matched changes from baseline QTcI of 3 milliseconds, which is commonly used for drugs with negative cardiac risk in preclinical studies. The sample size was considered sufficient to provide at least 80% power to show that the upper limit of the 90% confidence interval (2-sided) for the comparison of laquinimod to placebo would fall below 10 milliseconds.
The primary variable was defined as the timematched change from baseline, using an individual QTc correction method (QTcI). QTcI provides an optimization of QT interval adjustment for changes in heart rate (HR) and is determined from the slope (β) of the QT-RR relationship (from day -1 ECGs) for each individual subject using the equation QTcI = QT/(RR). Mean values from the quadruplicate ECGs at each time point were used in the analyses.
The primary analysis was based on the time-matched change from baseline analysis of the mean differences in QTcI between laquinimod (day 14) and placebo, the delta delta approach (ddQTcI). This is performed for each of the 10 time points to define whether anyone has a ddQTcI change in which the upper 95%CI (1-sided) exceeds 10 milliseconds as per ICH E14 guidelines. The effect of gender on ddQTcI was also investigated via the general linear mixed effects model. In addition, QT intervals corrected for heart rate using Friderica's and Bazett's QT correction methods were provided for historical purposes only and considered secondary.
Assay sensitivity analysis was assessed by comparing the ddQTcI estimates of moxifloxacin and confirmed if the lower limit of the 2-sided 90%CI was above 5 milliseconds in at least 1 time point from 1 to 6 hours postdose. A time-averaged analysis was also conducted in which, for each subject, the mean of all baseline time points was subtracted from the mean of all postbaseline time points for day 14.
An exploratory outlier analysis was conducted, based on this time-averaged analysis and the following criteria: maximum change in QTc interval from baseline of ࣙ30-60 milliseconds and of >60 milliseconds. Absolute QTc intervals >500, >480, and >450 milliseconds (QTcI, QTcF, and QTcB) at postdose when absolute QTc intervals were <500, <480, and <450 milliseconds at baseline, respectively. Change from baseline >25% in PR interval and QRS interval (increase) and HR (increase or decrease reflecting a HR > 100 bpm or HR < 50 bpm). Morphological analyses were performed to assess changes in ECG waveforms from baseline to day 14.
Pharmacokinetic parameters were calculated using nominal time from individual plasma concentrationtime data by model-independent analysis methods using WinNonlin TM version 5.0.
1. An analysis of covariance was conducted (SAS version 9.1) on the log-transformed pharmacokinetic data with age and body mass index included as covariates. Gender, study drug, and gender by treatment effects were included in the model.
Pharmacokinetic-pharmacodynamic analysis via a linear mixed-effects modeling approach explored the relationship between ddQTcI and plasma concentrations of laquinimod (0.6-and 1.2-mg groups pooled together). The predicted population average ddQTcI and corresponding upper 95% (1-sided) CIs at C max were estimated. Presence of hysteresis was explored.
Results
Subjects
A total number of 200 healthy subjects (106 male and 94 female) were randomized in this study; 193 completed all study-related activities, and 195 were included in the ECG analysis. The first subject enrolled in the study in January 2008, and the last subject completed the study in May 2008. Two subjects withdrew consent, 3 subjects were discontinued by the investigator due to AEs, and 2 subjects were lost to follow-up before the end of study visit but after completing all PK and ECG assessments. For the subjects who withdrew due to AEs, 1 subject was in the placebo group (urinary tract infection) and the medication used to treat the urinary tract infection disqualified the subject from the study; 1 subject was in the laquinimod 0.6-mg group (rash considered probably related the study drug), and 1 subject in the laquiniod 1.2 mg group (acute monoarticular arthritis considered possibly related to the study drug). The majority of subjects (84%) were white. The treatment groups were well balanced with respect to age, gender, and other demographic characteristics (see Table 1 ).
Pharmacodynamic Findings
The time-matched analysis for ddQTcI revealed that the moxifloxacin group met the assay sensitivity criteria in that the mean and the lower bounds of the 2-sided 90%CI exceeded the threshold of 5 milliseconds at all time points between 1 and 12 hours postdose (see Table 2 , Figure 1 ). For both laquinimod dose groups the upper bounds of the 90%CIs of ddQTcI in the time matched analysis were well below the 10-millisecond threshold for regulatory significance at all time points. 17 QTcF and QTcB data showed similar results. A timeaveraged analysis (data not shown) demonstrated a mean ddQTcI for both laquinimod doses versus placebo of approximately 0 milliseconds compared to a mean change of approximately +10 milliseconds for moxifloxacin; there was no apparent effect of gender on these findings.
Outlier analysis showed that no subject in the study had a QTcI or QTcF value greater than 480 milliseconds. One subject from the laquinimod 1.2 mg/day group (2%), 2 from placebo (4%), and 7 from the moxifloxacin group (14%) had a change from baseline in QTcI of 30-60 milliseconds. One subject in the study, from the laquinimod 1.2 mg/day group, had an increase of QTcI >60 milliseconds but did not meet other outlier criteria. Further analysis did not show any remarkable findings with respect to laquinimod plasma concentrations or PK parameters, which were all well contained within the range presented by the laquinimod 1.2-mg dose group. The only new morphologic changes in ECG observed were related to new inverted T-waves appearing in 2 (4.3%) subjects on laquinimod 0.6 mg/day, 3 (6.1%) subjects in laquinimod 1.2 mg/day, 2 (4.0%) subjects on placebo, and 4 (8.2%) subjects from moxifloxacin, none of which were considered to be clinically significant. There was no evidence of an effect of laquinimod on heart rate or PR or QRS interval.
Pharmacokinetic Findings
After oral administration of laquinimod, the plasma concentrations increased quickly, reaching maximal concentrations within 1 hour (Table 3 ). The plasma concentrations declined thereafter with an average observed terminal-phase half-life of approximately 80 to 90 hours (see Figure 2A) . Laquinimod exposure generally increased in proportion to dose; that is, doubling of the dose of laquinimod increased the AUC, C max , and C min by approximately 2-fold. As expected from the long half-life, laquinimod fluctuation ratio was very low, with the day 14 C max /C min ratio being approximately 1.4.
Laquinimod C min was comparable from day 12 to 14, and similar between days 14 and 15, suggesting that laquinimod had achieved approximate steadystate plasma levels by day 14. Laquinimod exposure was statistically significantly higher (10% to 20%) in women compared to men in both dose groups (see Figure 2B ).
Pharmacokinetic/Pharmacodynamic Relationship
The relationship between ddQTcI and laquinimod plasma concentration taken from the combined laquinimod dose groups was associated with a flat to negative slope showing no signal of change in ddQTcI with increasing laquinimod levels ( Figure 3 ). The concentration:QTcI slope was -0.0058 with P < .0001. In the concentration:QTcI model, the predicted mean ddQTcI and upper bounds of the 1-sided 95%CI at the mean maximal plasma level with 0.6 mg/day were 1.0 and 2.2 milliseconds, and for 1.2 mg/day were -1.2 and 0.4 milliseconds, respectively. There was no indication of a hysteresis in ddQTcI. a All parameters are provided as means ± SD, except T max , which is given in medians and ranges. b The gender effect was statistically significant for C max (P < .001),AUC 24 (P = .01), and C min (P = .047).
Safety
No deaths or serious AEs were reported during this study. A total of 118 subjects (59.0%) experienced 336 treatment-emergent AEs over the course of the study. The most common AEs reported for 5% or more of subjects treated with either dose of laquinimod are presented in Table 4 . AEs appearing in more than 10% of subjects were headache (32%, 18%, 22%), pain in extremity (12%, 8%, 8%), and upper abdominal pain (10%, 4%, 0%) seen in laquinimod 1.2 mg, laquinimod 0.6 mg, and placebo groups, respectively. In terms of cardiac AEs, 1 subject in the laquinimod group experienced heart palpitations, and 2 subjects in the placebo group had increases in heart rate (9 and 12 beats/min). All AEs were mild to moderate in intensity. Three subjects were withdrawn from the study due to AEs, 1 in the 1.2 mg laquinimod group due to acute monoarticular arthritis considered possibly related to the study drug, 1 in the 0.6 mg group due to rash considered probably related the study drug, and 1 in the placebo group due to urinary tract infection who was discontinued because the medication to treat the urinary tract infection disqualified the subject from the study. There were no clinically significant changes in the clinical laboratory measures over the course of the study that could be reasonably associated with the treatments under investigation. No subjects were withdrawn due to abnormal laboratory values. All clinical laboratory values were reviewed by the clinical investigators, and follow-up was completed as requested, with value normalization shown on further testing. There were no clinically significant findings from assessments of ECGs, vital signs, or physical examinations.
Discussion
The primary objective of this study was to assess the potential effects of laquinimod on cardiac repolarization at 2 dose levels: 0.6 and 1.2 mg/day. This study was designed in compliance with the ICH E14 guidance, 17 the key elements of which included (1) the use of a positive control (moxifloxacin), (2) characterization of the concentration:QTc relationship, (3) reducing variability in the QTc interval measurements such as quadruplicate ECGs at each time point and use of a centralized core ECG laboratory, and (4) sufficient sample size to exclude a 10-millisecond QTc prolongation using the upper arm of the 95% 1-sided CI.
The primary analysis, based on the difference between laquinimod and placebo in time-matched baseline-corrected QTcI, demonstrated no evidence of QTc prolongation, and hence cardiac repolarization, in healthy subjects. The pharmacokinetic/ pharmacodynamic analysis, which presents the relationship between change from baseline of QTcI duration and plasma drug concentration, demonstrated no sign of any effect of laquinimod on QTcI up to approximately 1200 ng/mL. Furthermore, with the ddQTcI (ie, placebo-corrected change from baseline QTc interval) data demonstrating upper CIs below the cardiovascular threshold of concern of 10 milliseconds, there is no apparent concern that laquinimod causes an effect on cardiac repolarization. No gender differences were observed for effects of laquinimod on QTcI. There were also no notable changes in ECG morphology or other ECG parameters, suggesting that laquinimod has no effect on AV conduction or cardiac depolarization at doses up to 1.2 mg/day.
The validity of this study was demonstrated by a robust QTcI prolongation with moxifloxacin. Mean maximal moxifloxacin ddQTcI of 16 milliseconds was reached at 4 hours postdose, which is approximately the T max of moxifloxacin after oral ingestion. 23 A mean ddQTcI > 10 milliseconds was seen at all time points from 1 to 12 hours postdose. It is noteworthy to mention that the moxifloxacin tablets used in this study were overencapsulated to ensure complete double-blinding during the entire study. Results of in vitro dissolution tests performed before study initiation demonstrated that the dissolution rate of the encapsulated tablets is similar to that of the original tablets. Both products reach the same levels of dissolution throughout the study, suggesting that encapsulation of the marketed product is not expected to have any effect on its rate and extent of exposure in vivo. The pharmacodynamic results from this and other TQT studies 9, 24, 25 confirmed that overencapsulation did not result in any meaningful change of the QT effect and support the use of encapsulated moxifloxacin as a positive control in TQT studies. Overall, the pharmacokinetic data in this study were consistent with data from other laquinimod studies. 10, 26 A small effect of gender was observed for laquinimod exposure, it generally being 10% to 20% higher in women compared to men.
The most common AEs reported in this study, including headache, pain in an extremity, and abdominal pain, are consistent with the known AE profile of laquinimod. 10, 12, 13, 27 Elevations in liver enzymes occurred in subjects treated with laquinimod and were either transient or considered not clinically significant.
This study was conducted in 2008 in accordance with the original ICH E14 guidance on assessing the effects on the QTc interval for nonantiarrhythmic drugs, which had been in effect since May 2005. 17 A study to assess the possibility of detecting effects on QTc during earlyphase clinical trials provided evidence that robust QTc assessment with concentration:QTc relationship analysis in first-in-human dose escalation studies can provide an alternative to the TQT study. 28 Results from the IQ-CSRC prospective study support replacement of the TQT study by QT assessment in the early clinical phase. 28 Since the acceptance of the concentration-QTc relationship as an alternative to the TQT study by regulatory agencies, 29 pharmaceutical companies have been implementing this methodology as part of their early clinical phase objectives.
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Conclusions
The results of this TQT study, consistent with preclinical data, showed no sign of any effect of laquinimod up to 1.2 mg/day on QTc interval, heart rate, AV conduction, PR and QRS intervals, or ECG morphology. The lack of correlation between laquinimod plasma concentrations and QTcI interval duration across the concentrations tested is indicative of an absence of dose-dependent effect on cardiac repolarization. 
